DYN

15.4603.56%
JP

Jason P. Rhodes

Independent Chairman

Mr. Jason P. Rhodes, M.B.A., is a Partner of Atlas Venture Advisors, Inc., which he joined on October 1, 2014. He is also a Partner of Atlas Venture Life Science Advisors LLC. He serves as Acting Chief Executive Officer and Director of Raze Therapeutics, Inc. since October 14, 2014. He is Independent Chairman of Dyne Therapeutics, Inc. since November 2018 and Chairman of KaryoVerse. He also serves as a Director of Zyngenia, Inc. since October 11, 2012, Accent Therapeutics, Inc., Rectify Pharmaceuticals, Inc., K36 Therapeutics, Inc., AAVantgarde Bio s.r.l. since June 2023, and Weaver. Additionally, he serves on the Advisory Board of the Vagelos Program in Life Sciences and Management at the University of Pennsylvania and on the Board of Trustees of the American Academy in Rome. Previously, Mr. Rhodes served as a Director of Be Biopharma, Inc. until May 2026. At Generation Bio Co., he served as an Independent Director from October 2025 to February 2026 and as Independent Chairman from October 2017 to October 2025. He was employed at Third Harmonic Bio, Inc. until 2022, where he served as President and as an Independent Director from June 2019. He served as an Independent Director of Replimune Group, Inc. from September 2015 to June 2022. He is Co-Founder of Disarm Therapeutics, Inc. and served as its Chairman and founding Chief Executive Officer. At Dyne Therapeutics, Inc., he also served as founding Chief Executive Officer. At Rectify Pharmaceuticals, Inc., he served as Executive Chair of the Board and as founding Chief Executive Officer. He also served as Chairman of Mithril. Mr. Rhodes was President, Chief Financial Officer and Principal Accounting Officer of Epizyme, Inc. from March 2010 to December 31, 2014. He is Co-Founder of Fidelity Biosciences (now F-Prime Capital) and also served as a Partner. He was Vice President of Business Development of Alnylam Pharmaceuticals, Inc., which he joined in 2007, and Vice President of Acquisitions of Internet Healthcare Group, LLC. His prior directorships include Bicycle Therapeutics plc from 2015 to 2019, Replimune Limited from 2015 to 2017, Gemini Therapeutics, Inc. from April 2016, FORUM Pharmaceuticals Inc., Tetraphase Pharmaceuticals, Inc., ActiveCyte Inc., and Mersana Therapeutics, Inc. He focuses on creating and building novel therapeutics companies in Life Science. Mr. Rhodes received a B.A. in History from Yale University in 1991 and an M.B.A. from The Wharton School of the University of Pennsylvania in 1996.

Positions